An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

In an era where chronic diseases are reshaping global health priorities, the diabetic retinopathy market stands out as a ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

Eye floaters, those drifting spots in your vision, are often harmless but can signal hypertension or diabetes. High blood ...

MUSCAT: The National Programme for Early Detection of Diabetic Retinopathy using artificial intelligence (AI) technologies ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative ...